Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

(Neutral)

(Positive)

Rhea-AI Summary

Pacira BioSciences (Nasdaq:PCRX) granted inducement equity awards on July 2, 2026 to ten new employees under its 2014 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).

Four employees received stock options for 9,200 shares and ten employees received 18,200 restricted stock units, each with multi-year vesting tied to continued employment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Positive

Inducement equity awards granted to 10 new employees under Nasdaq rule
Stock options and RSUs feature multi-year vesting tied to retention

Negative

Potential dilution from up to 27,400 shares of new equity awards

What This Means

New-hire inducement grants covering 9,200 option shares and 18,200 RSUs add modest dilution but foll...

Analysis

New-hire inducement grants covering 9,200 option shares and 18,200 RSUs add modest dilution but follow a period of net insider selling around 41,374 shares and elevated short interest above 16%. Monitoring future equity awards and insider activity remains important.

Key Figures

Stock options granted: 9,200 shares RSUs granted: 18,200 shares Option term: 10 years +5 more

8 metrics

Stock options granted 9,200 shares Aggregate options to four new employees under Inducement Plan

RSUs granted 18,200 shares Aggregate restricted stock units to ten new employees

Option term 10 years Contractual term of the inducement stock options

Vesting period 4 years Equity awards vest over four years

Initial vesting tranche 25 percent Options vest 25 percent on first employment anniversary

Subsequent vesting period 36 months Remaining option shares vest in equal quarterly installments

Option exercise price $25.39 per share Equal to closing price on grant date, July 2, 2026

RSU vesting start July 1, 2027 RSUs vest annually in four equal installments beginning on this date

Historical Context

5 past events · Latest: Jul 01 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 01	Reimbursement update	Positive	-1.3%	UnitedHealthcare began separate EXPAREL reimbursement covering about 40 million members.
Jun 30	Asset divestiture deal	Positive	+1.1%	Agreement to sell iovera° business to Zimmer Biomet for up to $140 million.
Jun 09	Director elections	Neutral	+0.9%	All three company director nominees were elected at the 2026 annual meeting.
Jun 04	Proxy campaign update	Neutral	+0.3%	Company urged support for its board slate amid activist contest using BLUE proxy card.
May 28	Activist criticism	Negative	-1.5%	DOMA Perpetual Capital criticized the board for perceived long-term value destruction.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent headlines have mostly seen the share price move in line with the perceived positivity or negativity of each event, with one notable divergence on favorable reimbursement news.

Regulatory & Risk Context

Short Interest: 16.24%

Short Interest

16.24% of float

0% 15% 30%+

moderate as of 2026-06-15 Days to cover: 16.69

Short interest sits at an elevated level, suggesting that sentiment is cautious and that the shares may be prone to sharper moves if positions are forced to adjust.

Key Terms

nasdaq listing rule 5635(c)(4), restricted stock units, vesting schedule, exercise price

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

restricted stock units financial

"ten employees received restricted stock units for an aggregate of 18,200 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting schedule financial

"The stock options have a 10-year term and a four-year vesting schedule"

A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.

exercise price financial

"The stock options have an exercise price of $25.39 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

07/08/2026 - 08:00 AM

BRISBANE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on July 2, 2026 to ten new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.

Four employees received stock options to purchase an aggregate of 9,200 shares of Pacira common stock and ten employees received restricted stock units for an aggregate of 18,200 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient’s first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of $25.39 per share, the closing trading price of Pacira common stock on the Nasdaq Global Select Market on the date of grant. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on July 1, 2027.

Vesting of the equity awards is subject to the employee’s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera^®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.

Investor Contact:
Susan Mesco, (973) 451-4030
susan.mesco@pacira.com

Media Contact:
Sara Marino, (973) 370-5430
sara.marino@pacira.com

FAQ

What inducement grants did Pacira (NASDAQ:PCRX) announce on July 8, 2026?

Pacira announced inducement equity awards for ten new employees, including stock options and restricted stock units. According to Pacira, options cover 9,200 shares and RSUs cover 18,200 shares of common stock, all granted under its Amended and Restated 2014 Inducement Plan.

How many Pacira (PCRX) shares are covered by the new inducement awards?

The inducement awards cover a total of 27,400 Pacira common shares. According to Pacira, four employees received options for 9,200 shares and ten employees received 18,200 restricted stock units, each RSU representing the contingent right to receive one share.

What are the vesting terms for Pacira (PCRX) July 2026 stock options?

The stock options vest over four years with a one-year cliff. According to Pacira, 25% vests on the first employment anniversary, with the remaining shares vesting in equal quarterly installments over the next 36 months, subject to continued employment.

What is the exercise price and term of Pacira (PCRX) inducement stock options?

The inducement stock options have a ten-year term and a fixed exercise price. According to Pacira, the exercise price is $25.39 per share, equal to the July 2, 2026 Nasdaq Global Select Market closing price of Pacira common stock.

How do Pacira (PCRX) restricted stock units from July 2026 vest?

The restricted stock units vest annually in four equal installments. According to Pacira, vesting begins on July 1, 2027, with each RSU representing the contingent right to receive one Pacira common share, subject to the employee’s continued employment with the company.

Why did Pacira (PCRX) grant equity awards under Nasdaq Listing Rule 5635(c)(4)?

Pacira used inducement awards as a material incentive for new hires. According to Pacira, the grants were made under its 2014 Inducement Plan and approved by the Board’s People & Compensation Committee without stockholder approval, consistent with Nasdaq Listing Rule 5635(c)(4).